Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267511 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT03267511: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT03267511 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03267511, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether spherical silica can achieve similar or greater extrinsic dental stain and plaque removal, in comparison to dentifrices containing higher concentrations of standard abrasive silica, and how the addition of 5% sodium tripolyphosphate (STP) enhances cleaning capability.
Primary Outcome
An assessment of the area and intensity of dental stain on the study teeth was performed using the MLSI to evaluate ranking order in extrinsic dental stain removal or reduction of test product 1, test product 2, reference product 1, reference product 2; after usage for 8 weeks, twice daily brushing. The intensity of stain was scored separately for the gingival and body areas of each assessable tooth on a scale of 0 to 3 (0 - no stain, 1- light stain, 2 - moderate stain, 3 - heavy stain). The are
Interventions
- DRUG 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica
- DRUG 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP
- DRUG 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica
- DRUG 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2017-12-02 |
| Phase | Phase 2 |
What the finished NCT03267511 record still lists
NCT03267511 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica is the first listed.
NCT03267511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03267511 about?
NCT03267511 is a clinical study titled "A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices". The purpose of this study is to determine whether spherical silica can achieve similar or greater extrinsic dental stain and plaque removal, in comparison to dentifrices containing higher concentrations of standard abrasive silica, and how the addition of 5% sodium tripolyphosphate (STP) enhances cl...
What is the current status of trial NCT03267511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2017-09-25. Estimated completion is 2017-12-02.
What interventions are being tested in trial NCT03267511?
The interventions under investigation include: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica (DRUG), 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP (DRUG), 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica (DRUG), 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP (DRUG).
Who is sponsoring clinical trial NCT03267511?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03267511's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI